Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal

Fineline Cube Jan 8, 2026
Company Deals

ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M

Fineline Cube Jan 8, 2026
Company Deals

Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront

Fineline Cube Jan 8, 2026
Company Deals

Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy

Fineline Cube Jan 8, 2026
Company Deals

Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance

Fineline Cube Jan 8, 2026
Policy / Regulatory

NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs

Fineline Cube Jan 6, 2026
Company Drug

Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer

Fineline Cube Jan 8, 2026
Company Deals Drug

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal

Fineline Cube Jan 8, 2026
Company Drug

Huadong Medicine’s HDM1010 Gets FDA Nod for Phase I Trial in T2D

Fineline Cube Jun 10, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...

Company Deals

Sanyou Biopharma Partners with Medicovestor to Advance Next-Gen ADCs

Fineline Cube Jun 10, 2025

China-based Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced a strategic partnership with US-headquartered Medicovestor, Inc. to...

Company

Huahai Pharma Receives FDA Warning Letter After Inspection

Fineline Cube Jun 10, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received a warning...

Company

Burning Rock Reports Q1 2025 Revenue Growth and R&D Progress

Fineline Cube Jun 9, 2025

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) released its Q1 2025 financial report, showing a...

Company Deals

Sinopep Allsino Partners with Vazyme to Advance Synthetic Biology

Fineline Cube Jun 9, 2025

China-based Jiangsu Sinopep Allsino Biopharmaceutical Co., Ltd. (SHA: 688076) announced a strategic partnership with compatriot...

Company Deals

CIRC and Qianlong International Collaborate to Advance BNCT and Nuclear Medicine

Fineline Cube Jun 9, 2025

China Isotope & Radiation Corporation (CIRC; HKG: 1763) and Hong Kong-based Qianlong International Holdings Ltd....

Company Drug

AstraZeneca’s Calquence Combo Approved by EU for CLL Treatment

Fineline Cube Jun 9, 2025

UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) announced that the European Commission (EC) has approved its...

Company Drug

Bayer’s CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD

Fineline Cube Jun 9, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced results from the Phase II CONFIDENCE study,...

Company Deals

Lifetech Scientific Plans RMB 150 Million Investment in AffectOR MedTech

Fineline Cube Jun 9, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) announced plans to invest RMB 150 million (USD 21...

Company Deals

OBI Pharma Partners with TegMine to Develop Antibody-Drug Conjugates

Fineline Cube Jun 9, 2025

Taiwan-based OBI Pharma announced a collaboration with San Francisco-based TegMine Therapeutics, Inc. to develop antibody-drug...

Company Drug

NeoCura Bio-Medical Gains NMPA Approval for mRNA Cancer Vaccine Trial

Fineline Cube Jun 9, 2025

China-based NeoCura Bio-Medical Technology Co., Ltd. announced that it has received approval from the National...

Company Drug

YolTech Receives FDA Clearance for PCSK9-Targeted Base Editing Drug YOLT-101

Fineline Cube Jun 9, 2025

Shanghai-based YolTech Therapeutics announced that it has received clearance from the US Food and Drug...

Company Deals

Kindstar Global Partners with Biostate AI to Advance Precision Medicine

Fineline Cube Jun 9, 2025

China-based Kindstar Global (HKG: 9960) announced the establishment of a joint venture (JV) with US-headquartered...

Company Medical Device

Genesis MedTech Wins NMPA Approval for Locally Developed Thrombus Aspiration Catheter

Fineline Cube Jun 9, 2025

Singapore-based Genesis MedTech announced that it has received marketing approval from China’s National Medical Products...

Company Deals

Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China

Fineline Cube Jun 6, 2025

China’s Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced a collaboration agreement with Merck KGaA...

Company Drug

HELP Therapeutics’ iPSC-Derived Cardiomyocyte Therapy Enters US Clinical Trials

Fineline Cube Jun 6, 2025

Nanjing-based HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, announced that its innovative induced...

Company Deals

Lancet Robotics Secures Series A+ Funding for Surgical Robot Development

Fineline Cube Jun 6, 2025

Shenzhen-based Lancet Robotics, a developer of orthopedic joint replacement surgical robots, has reportedly secured “tens...

Legal / IP

Biocytogen’s RenMab Platform Wins Japanese Patent, Expanding IP Portfolio

Fineline Cube Jun 6, 2025

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that its RenMab platform, a key...

Company Deals Drug

Bayer’s Vividion Gains Global Rights to WRN Inhibitor VVD-214

Fineline Cube Jun 6, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced that its wholly owned subsidiary Vividion Therapeutics,...

Company Deals

Nanjing Leads Biolabs Files for Hong Kong IPO Amid Product Pipeline Progress

Fineline Cube Jun 6, 2025

China-based Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotech company focusing on oncology and autoimmune...

Posts pagination

1 … 87 88 89 … 605

Recent updates

  • Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer
  • Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal
  • Sanofi’s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia
  • Bayer’s Cevatertinib Wins Breakthrough Therapy Designation for HER2‑Mutant NSCLC
  • ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer

Company Deals Drug

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal

Company Drug

Sanofi’s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia

Company Drug

Bayer’s Cevatertinib Wins Breakthrough Therapy Designation for HER2‑Mutant NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.